SCHEMBL752487

SCHEMBL752487

C[Si](C)(C)CBr.[MgH2]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1224449 0.95
SCHEMBL10398333 0.90
SCHEMBL17138356 0.70
SCHEMBL17138289 0.70
SCHEMBL12000716 0.70
SCHEMBL9007252 0.69
SCHEMBL8207543 0.67
SCHEMBL125830 0.67
SCHEMBL1262675 0.67
SCHEMBL10794391 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115746053-A Si-PCCP ligand, preparation method thereof, ethylene oligomerization catalyst and application thereof 万华化学集团股份有限公司 2023-03-07 CN claimed
CN-117050214-A Method for producing fluorinated solid oxides and use thereof in metallocene-based catalyst systems 切弗朗菲利浦化学公司 2023-11-14 CN disclosed
CN-112672821-B Method for producing fluorinated solid oxides and use thereof in metallocene-based catalyst systems 切弗朗菲利浦化学公司 2023-11-07 CN disclosed
CN-115746053-A Si-PCCP ligand, preparation method thereof, ethylene oligomerization catalyst and application thereof 万华化学集团股份有限公司 2023-03-07 CN disclosed
EP-2429993-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INT (DE) 2015-01-21 EP disclosed
US-8841331-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2014-09-23 US disclosed
US-20130203747-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION GILEAD SCIENCES, INC. (US) 2013-08-08 US disclosed
US-8338441-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2012-12-25 US disclosed
EP-2429993-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Gilead Sciences, Inc. (US) 2012-03-21 EP disclosed
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-11-18 US disclosed
WO-2004074333-A2 PROCESS FOR HOMO- OR COPOLYMERIZATIONOF CONJUGATED OLEFINES DOW GLOBAL TECHNOLOGIES INC. (US) 2004-09-02 WO disclosed
EP-1394162-A1 Intermediates of azole antifungal agents and processes for the preparation thereof Eisai Co., Ltd. (JP) 2004-03-03 EP disclosed
EP-1394142-A1 Carboxylic acid intermediates of antifungal agents and processes for the preparation thereof Eisai Co., Ltd. (JP) 2004-03-03 EP disclosed
EP-1231210-A2 Azole antifungal agents, processes for the preparation thereof, and intermediates Eisai Co., Ltd. (JP) 2002-08-14 EP disclosed
US-5792781-A EFFECTIVE AGAINST DERMATOMYCOSIS/VISCEROMYCOSIS CAUSED BY FUNGI, I.E., CANDIDA ALBICANS EISAI CO., LTD. (JP) 1998-08-11 US disclosed
US-5789429-A FUNGICIDE EISAI CO., LTD. (JP) 1998-08-04 US disclosed
US-5648372-A TRIAZOLES EISAI CO., LTD. (JP) 1997-07-15 US disclosed
EP-0667346-A2 Azole antifungal agents, process for the preparation there of and intermediates Eisai Co., Ltd. (JP) 1995-08-16 EP disclosed
US-5164524-A Process for preparing tetra (organyl) telluride compounds THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1992-11-17 US disclosed
US-5157154-A Tetra (organyl) tellurium compounds and process for preparing same THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1992-10-20 US disclosed